Home » Stocks » Kindred Biosciences

Kindred Biosciences, Inc. (KIN)

Stock Price: $4.04 USD 0.06 (1.51%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 159.05M
Revenue (ttm) 3.98M
Net Income (ttm) -29.74M
Shares Out 39.37M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $4.04
Previous Close $3.98
Change ($) 0.06
Change (%) 1.51%
Day's Open 3.97
Day's Range 3.92 - 4.10
Day's Volume 144,673
52-Week Range 3.11 - 11.93

More Stats

Market Cap 159.05M
Enterprise Value 114.77M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.37M
Float 30.32M
EPS (basic) -0.77
EPS (diluted) -0.77
FCF / Share -0.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 497,971
Short Ratio 2.65
Short % of Float 2.30%
Beta 0.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 40.01
PB Ratio 1.81
Revenue 3.98M
Operating Income -29.18M
Net Income -29.74M
Free Cash Flow -22.09M
Net Cash 44.28M
Net Cash / Share 1.12
Gross Margin 92.30%
Operating Margin -734.14%
Profit Margin -69.70%
FCF Margin -555.82%
ROA -34.29%
ROE -30.46%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$11.64*
(188.12% upside)
Low
9.00
Current: $4.04
High
14.00
Target: 11.64
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue4.261.97------
Revenue Growth116.48%-------
Gross Profit3.671.64------
Operating Income-62.57-51.26-31.65-22.82-27.26-27.23-4.22-0.12
Net Income-61.39-49.69-30.88-22.50-27.13-27.14-4.21-0.12
Shares Outstanding38.6631.0025.0819.8719.7718.783.732.11
Earnings Per Share-1.59-1.60-1.23-1.13-1.37-1.44-1.13-0.06
Operating Cash Flow-56.34-45.04-21.88-18.78-22.76-21.93-1.57-0.06
Capital Expenditures-8.42-13.67-5.92-0.95-0.73-0.44-0.02-
Free Cash Flow-64.77-58.71-27.80-19.73-23.49-22.37-1.59-0.06
Cash & Equivalents71.7173.9381.0256.7673.0410165.330.94
Total Debt22.52-------
Net Cash / Debt49.1973.9381.0256.7673.0410165.330.94
Assets11410690.8261.5879.6210265.490.94
Liabilities32.1015.286.143.903.252.902.210.07
Book Value81.9291.2184.6857.6876.3799.0263.28-0.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kindred Biosciences, Inc.
Country United States
Employees 156
CEO Richard H. Chin

Stock Information

Ticker Symbol KIN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: KIN
IPO Date December 12, 2013

Description

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.